Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
Status:
Recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with
continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT)
according to both measurable residual disease (MRD) and results of genetic study performed at
baseline.